Stimulator of interferon genes (STING): A "new chapter" in virus-associated cancer research. Lessons from wild-derived mouse models of innate immunity

Cytokine and Growth Factor Reviews

Volumn 29, Issue , 2016, Pages 83-91

  Poltorak, Alexander ^a,b   Kurmyshkina, Olga ^b   Volkova, Tatyana ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PETROZAVODSK STATE UNIVERSITY   (Russian Federation)

Author keywords

Cancer; DMXAA; Mouse model; Oncovirus; STING

Indexed keywords

ALPHA INTERFERON RECEPTOR; CISPLATIN; ETOPOSIDE; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 2; MANNOSE RECEPTOR; PATTERN RECOGNITION RECEPTOR; POLYCYCLIC AROMATIC HYDROCARBON; PROTEIN SERINE THREONINE KINASE; STIMULATOR OF INTERFERON GENES; T LYMPHOCYTE RECEPTOR; TANK BINDING KINASE 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR PROTEIN; UNCLASSIFIED DRUG; VADIMEZAN; MEMBRANE PROTEIN; MPYS PROTEIN, HUMAN; MPYS PROTEIN, MOUSE;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; APOPTOSIS; BINDING SITE; CELL PROLIFERATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; DIMERIZATION; DNA POLYMORPHISM; ENZYME ACTIVE SITE; HYDROPHOBICITY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; INNATE IMMUNITY; INTERFERON PRODUCTION; LIGAND BINDING; MOUSE; NONHUMAN; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN TARGETING; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR VASCULARIZATION; UTERINE CERVIX CANCER; VIRUS CARCINOGENESIS; WART VIRUS; ANIMAL; HUMAN; IMMUNOLOGY; NEOPLASM; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; PATHOLOGY; VIROLOGY; VIRUS CELL TRANSFORMATION;

ANIMALS; CELL TRANSFORMATION, VIRAL; HUMANS; IMMUNITY, INNATE; MEMBRANE PROTEINS; MICE; NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS;

EID: 84960192170     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2016.02.009     Document Type: Short Survey

References (80)

1. Bhat N., Fitzgerald K.A. Recognition of cytosolic DNA by cGAS and other STING-dependent sensors. Eur. J. Immunol. 2014, 44:634-640. 10.1002/eji.201344127.
2. Chow J., Franz K.M., Kagan J.C. PRRs are watching you: localization of innate sensing and signaling regulators. Virology 2015, 479-480:104-109. 10.1016/j.virol.2015.02.051.
3. Dempsey A., Bowie A.G. Innate immune recognition of DNA: a recent history. Virology 2015, 479-480:146-152. 10.1016/j.virol.2015.03.013.
4. Ishikawa H., Barber G.N. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 2008, 455:674-678. 10.1038/nature07317.
5. Zhong B., Yang Y., Li S., Wang Y.Y., Li Y., Diao F., et al. The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor activation. Immunity 2008, 29(4):538-550. 10.1016/j.immuni.2008.09.003.
6. Sun W., Li Y., Chen L., Chen H., You F., Zhou X., et al. ERIS, an endoplasmic reticulum IFN stimulator, activates innate immune signaling through dimerization. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:8653-8658. 10.1073/pnas.0900850106.
7. Liu X., Wang C. The emerging roles of the STING adaptor protein in immunity and diseases. Immunology 2015, 10.1111/imm.12561.
8. Saitoh T., Fujita N., Hayashi T., Takahara K., Satoh T., Lee H., et al. Atg9a controls dsDNA-driven dynamic translocation of STING and the innate immune response. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:20842-20846. 10.1073/pnas.0911267106.
9. Tanaka Y., Chen Z.J. STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway. Sci. Signal. 2012, 5:ra20. 10.1126/scisignal.2002521.
10. Unterholzner L., Keating S.E., Baran M., Horan K.A., Jensen S.B., Sharma S., et al. IFI16 is an innate immune sensor for intracellular DNA. Nat. Immunol. 2010, 11:997-1004. 10.1038/ni.1932.
11. Burdette D.L., Monroe K.M., Sotelo-Troha K., Iwig J.S., Eckert B., Hyodo M., et al. STING is a direct innate immune sensor of cyclic di-GMP. Nature 2011, 478:515-518. 10.1038/nature10429.
12. Sun L., Wu J., Du F., Chen X., Chen Z.J. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 2013, 339:786-791. 10.1126/science.1232458.
13. Archer K.A., Durack J., Portnoy D.A. STING-dependent type I IFN production inhibits cell-mediated immunity to Listeria monocytogenes. PLoS Pathog. 2014, 10(1):e1003861. 10.1371/journal.ppat.1003861.
14. Hansen K., Prabakaran T., Laustsen A., Jørgensen S.E., Rahbæk S.H., Jensen S.B., et al. Listeria monocytogenes induces IFNβ expression through an IFI16-, cGAS- and STING-dependent pathway. EMBO J. 2014, 33:1654-1666. 10.15252/embj.201488029.
15. Ablasser A., Goldeck M., Cavlar T., Deimling T., Witte G., Röhl I., et al. cGAS produces a 2'-5'-linked cyclic dinucleotide second messenger that activates STING. Nature 2013, 498:380-384. 10.1038/nature12306.
16. Diner E.J., Burdette D.L., Wilson S.C., Monroe K.M., Kellenberger C.A., Hyodo M., et al. The innate immune DNA sensor cGAS produces a noncanonical cyclic dinucleotide that activates human STING. Cell. Rep. 2013, 3:1355-1361. 10.1016/j.celrep.2013.05.009.
17. Conlon J., Burdette D.L., Sharma S., Bhat N., Thompson M., Jiang Z., et al. Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid. J. Immunol. 2013, 190:5216-5225. 10.4049/jimmunol.1300097.
18. Gao P., Ascano M., Zillinger T., Wang W., Dai P., Serganov A.A., et al. Structure-function analysis of STING activation by c[G(2',5') pA(3',5') p] and targeting by antiviral DMXAA. Cell 2013, 154:748-762. 10.1016/j.cell.2013.07.023.
19. Cavlar T., Deimling T., Ablasser A., Hopfner K.P., Hornung V. Species-specific detection of the antiviral small-molecule compound CMA by STING. EMBO J. 2013, 32:1440-1450. 10.1038/emboj.2013.86.
20. Yi G., Brendel V.P., Shu C., Li P., Palanathan S., Cheng Kao C. Single nucleotide polymorphisms of human STING can affect innate immune response to cyclic dinucleotides. PLoS One 2013, 8:e77846. 10.1371/journal.pone.0077846.
21. Liu Y., Jesus A.A., Marrero B., Yang D., Ramsey S.E., Montealegre Sanchez G.A., et al. Activated STING in a vascular and pulmonary syndrome. N. Engl. J. Med. 2014, 371:507-518. 10.1056/NEJMoa1312625.
22. Guénet J.L., Bonhomme F. Wild mice: an ever-increasing contribution to a popular mammalian model. Trends Genet. 2003, 19:24-31.
23. Yang H., Wang J.R., Didion J.P., Buus R.J., Bell T.A., Welsh C.E., et al. Subspecific origin and haplotype diversity in the laboratory mouse. Nat. Genet. 2011, 43:648-655. 10.1038/ng.847.
24. Conner J.R., Smirnova I.I., Poltorak A. Forward genetic analysis of Toll-like receptor responses in wild-derived mice reveals a novel antiinflammatory role for IRAK1BP1. J. Exp. Med. 2008, 205:305-314. 10.1084/jem.20071499.
25. Conner J.R., Smirnova I.I., Poltorak A. A mutation in Irak2c identifies IRAK-2 as a central component of the TLR regulatory network of wild-derived mice. J. Exp. Med. 2009, 206:1615-1631. 10.1084/jem.20090490.
26. Conner J.R., Smirnova I.I., Moseman A.P., Poltorak A. IRAK1BP1 inhibits inflammation by promoting nuclear translocation of NF-kappaB p50. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:11477-11482. 10.1073/pnas.1006894107.
27. Moseman A.P., Moseman E.A., Schworer S., Smirnova I., Volkova T., von Andrian U., Poltorak A. Mannose receptor 1 mediates cellular uptake and endosomal delivery of CpG-motif containing oligodeoxynucleotides. J. Immunol. 2013, 191:5615-5624. 10.4049/jimmunol.1301438.
28. Schworer S.A., Smirnova I.I., Kurbatova I., Bagina U., Churova M., Fowler T., et al. Toll-like receptor-mediated down-regulation of the deubiquitinase cylindromatosis (CYLD) protects macrophages from necroptosis in wild-derived mice. J. Biol. Chem. 2014, 289:14422-14433. 10.1074/jbc.M114.547547.
29. Surpris G., Chan J., Thompson M., Ilyukha V., Liu B.C., Atianand M., et al. Cutting edge: novel tmem173 allele reveals importance of STING N terminus in trafficking and type I IFN production. J. Immunol. 2015, (pii: 1501415).
30. Chen H., Pei R., Zhu W., Zeng R., Wang Y., Wang Y., et al. An alternative splicing isoform of MITA antagonizes MITA-mediated induction of type I IFNs. J. Immunol. 2014, 192:1162-1170. 10.4049/jimmunol.1300798.
31. Dong G., You M., Ding L., Fan H., Liu F., Ren D., Hou Y. STING negatively regulates double-stranded DNA-activated JAK1-STAT1 signaling via SHP-1/2 in B cells. Mol. Cells. 2015, 38:441-451. 10.14348/molcells.2015.2359.
32. Berg R.K., Rahbek S.H., Kofod-Olsen E., Holm C.K., Melchjorsen J., Jensen D.G., et al. T cells detect intracellular DNA but fail to induce type I IFN responses: implications for restriction of HIV replication. PLoS One 2014, 9:e84513. 10.1371/journal.pone.0084513.
33. Bhatelia K., Singh A., Tomar D., Singh K., Sripada L., Chagtoo M., et al. Antiviral signaling protein MITA acts as a tumor suppressor in breast cancer by regulating NF-κB induced cell death. Biochim. Biophys. Acta 2014, 1842:144-153. 10.1016/j.bbadis.2013.11.006.
34. Malik P., Zuleger N., de las Heras J.I., Saiz-Ros N., Makarov A.A., Lazou V., et al. NET23/STING promotes chromatin compaction from the nuclear envelope. PLoS One 2014, 9:e111851. 10.1371/journal.pone.0111851.
35. Low D., DeGruttola A.K., Poltorak A., Mizoguchi A., Mino-Kenudson M., Mizoguchi E. High endogenous expression of chitinase 3-Like 1 and excessive epithelial proliferation with colonic tumor formation in MOLF/EiJ mice. PLoS One 2015, 10:e0139149. 10.1371/journal.pone.0139149.
36. Lemos H., Huang L., McGaha T.L., Mellor A.L. Cytosolic DNA sensing via the stimulator of interferon genes adaptor: Yin and Yang of immune responses to DNA. Eur. J. Immunol. 2014, 44:2847-2853. 10.1002/eji.201344407.
37. Ohkuri T., Ghosh A., Kosaka A., Sarkar S.N., Okada H. Protective role of STING against gliomagenesis: rational use of STING agonist in anti-glioma immunotherapy. Oncoimmunology 2015, 4(4):e999523.
38. Zhu Q., Man S.M., Gurung P., Liu Z., Vogel P., Lamkanfi M., Kanneganti T.D. Cutting edge: sTING mediates protection against colorectal tumorigenesis by governing the magnitude of intestinal inflammation. J. Immunol. 2014, 193:4779-4782. 10.4049/jimmunol.1402051.
39. Ahn J., Konno H., Barber G.N. Diverse roles of STING-dependent signaling on the development of cancer. Oncogene 2015, 34:5302-5308. 10.1038/onc.2014.457.
40. Härtlova A., Erttmann S.F., Raffi F.A., Schmalz A.M., Resch U., Anugula S., et al. DNA damage primes the type I interferon system via the cytosolic DNA sensor STING to promote anti-microbial innate immunity. Immunity 2015, 42:332-343. 10.1016/j.immuni.2015.01.012.
41. Gajewski T.F., Corrales L. New perspectives on type I IFNs in cancer. Cytokine Growth Factor Rev. 2015, 26:175-178. 10.1016/j.cytogfr.2015.01.001.
42. Chandra D., Quispe-Tintaya W., Jahangir A., Asafu-Adjei D., Ramos I., Sintim H.O., et al. STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer. Cancer Immunol. Res. 2014, 2:901-910. 10.1158/2326-6066.CIR-13-0123.
43. Woo S.R., Fuertes M.B., Corrales L., Spranger S., Furdyna M.J., Leung M.Y., et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 2014, 41:830-842. 10.1016/j.immuni.2014.10.017.
44. Downey C.M., Aghaei M., Schwendener R.A., Jirik F.R. DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization. PLoS One 2014, 9:e99988. 10.1371/journal.pone.0099988.
45. Woo S.R., Corrales L., Gajewski T.F. The STING pathway and the T cell-inflamed tumor microenvironment. Trends Immunol. 2015, 36:250-256. 10.1016/j.it.2015.02.003.
46. Corrales L., Gajewski T.F. Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy. Cytokine 2016, 77:245-247. 10.1016/j.cyto.2015.08.258.
47. Deng L., Liang H., Xu M., Yang X., Burnette B., Arina A., et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 2014, 41:843-852. 10.1016/j.immuni.2014.10.019.
48. Baird J.R., Friedman D., Cottam B., Dubensky T.W., Kanne D.B., Bambina S., Bahjat K., Crittenden M.R., Gough M.J. Radiotherapy combined with novel STING-targeting oligonucleotides results in regression of established tumors. Cancer Res. 2015.
49. Wang Z., Celis E. STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice. Cancer Immunol. Immunother. 2015, 64:1057-1066. 10.1007/s00262-015-1713-5.
50. Barber G.N. STING: infection, inflammation and cancer. Nat. Rev. Immunol. 2015, 15:760-770. 10.1038/nri3921.
51. Gravekamp C., Chandra D. Targeting STING pathways for the treatment of cancer. Oncoimmunology 2015, 4:e988463.
52. Corrales L., Gajewski T.F. Molecular pathways targeting the stimulator of interferon genes (STING) in the immunotherapy of cancer. Clin. Cancer Res. 2015, 21:4774-4779. 10.1158/1078-0432.CCR-15-1362.
53. Lemos H., Huang L., McGaha T., Mellor A.L. STING, nanoparticles, autoimmune disease and cancer: a novel paradigm for immunotherapy?. Expert Rev. Clin. Immunol. 2015, 11:155-165. 10.1586/1744666X.2015.995097.
54. Sali T.M., Pryke K.M., Abraham J., Liu A., Archer I., Broeckel R., et al. Characterization of a Novel Human-Specific STING Agonist that Elicits Antiviral Activity Against Emerging Alphaviruses. PLoS Pathog. 2015, 11:e1005324. 10.1371/journal.ppat.1005324.
55. Nakamura T., Miyabe H., Hyodo M., Sato Y., Hayakawa Y., Harashima H. Liposomes loaded with a STING pathway ligand, cyclic di-GMP, enhance cancer immunotherapy against metastatic melanoma. J. Control Release. 2015, 216:149-157. 10.1016/j.jconrel.2015.08.026.
56. Yildiz S., Alpdundar E., Gungor B., Kahraman T., Bayyurt B., Gursel I., Gursel M. Enhanced immunostimulatory activity of cyclic dinucleotides on mouse cells when complexed with a cell-penetrating peptide or combined with CpG. Eur. J. Immunol. 2015, 45:1170-1179. 10.1002/eji.201445133.
57. Temizoz B., Kuroda E., Ohata K., Jounai N., Ozasa K., Kobiyama K., et al. TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN. Eur. J. Immunol. 2015, 45:1159-1169. 10.1002/eji.201445132.
58. Ahn J., Xia T., Konno H., Konno K., Ruiz P., Barber G.N. Inflammation-driven carcinogenesis is mediated through STING. Nat. Commun. 2014, 5:5166. 10.1038/ncomms6166.
59. Huang L., Li L., Lemos H., Chandler P.R., Pacholczyk G., Baban B., et al. Cutting edge: dNA sensing via the STING adaptor in myeloid dendritic cells induces potent tolerogenic responses. J. Immunol. 2013, 191:3509-3513. 10.4049/jimmunol.1301419.
60. White M.K., Pagano J.S., Khalili K. Viruses and human cancers: a long road of discovery of molecular paradigms. Clin. Microbiol. Rev. 2014, 27:463-481. 10.1128/CMR.00124-13.
61. Diner B.A., Lum K.K., Cristea I.M. The emerging role of nuclear viral DNA sensors. J. Biol. Chem. 2015, 290:26412-26421. 10.1074/jbc.R115.652289.
62. Reinholz M., Kawakami Y., Salzer S., Kreuter A., Dombrowski Y., Koglin S., et al. HPV16 activates the AIM2 inflammasome in keratinocytes. Arch Dermatol. Res. 2013, 305:723-732. 10.1007/s00403-013-1375-0.
63. Lo Cigno I., De Andrea M., Borgogna C., Albertini S., Landini M.M., Peretti A., et al. The Nuclear DNA Sensor IFI16 Acts as a restriction factor for human papillomavirus replication through epigenetic modifications of the viral promoters. J. Virol. 2015, 89:7506-7520. 10.1128/JVI.00013-15.
64. Karim R., Meyers C., Backendorf C., Ludigs K., Offringa R., van Ommen G.J., et al. Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes. PLoS One 2011, 6:e17848. 10.1371/journal.pone.0017848.
65. Doorbar J., Egawa N., Griffin H., Kranjec C., Murakami I. Human papillomavirus molecular biology and disease association. Rev. Med. Virol. 2015, 25(Suppl. 1):2-23. 10.1002/rmv.1822.
66. Tummers B., Burg S.H. High-risk human papillomavirus targets crossroads in immune signaling. Viruses 2015, 7:2485-2506. 10.3390/v7052485.
67. Ma Z., Jacobs S.R., West J.A., Stopford C., Zhang Z., Davis Z., et al. Modulation of the cGAS-STING DNA sensing pathway by gammaherpesviruses. Proc. Natl. Acad. Sci. U. S. A. 2015, 112:E4306-15. 10.1073/pnas.1503831112.
68. Lau L., Gray E.E., Brunette R.L., Stetson D.B. DNA tumor virus oncogenes antagonize the cGAS-STING DNA-sensing pathway. Science 2015, 350:568-571. 10.1126/science.aab3291.
69. Liu Y., Li J., Chen J., Li Y., Wang W., Du X., et al. Hepatitis B virus polymerase disrupts K63-linked ubiquitination of STING to block innate cytosolic DNA-sensing pathways. J. Virol. 2015, 89:2287-2300. 10.1128/JVI.02760-14.
70. Karim R., Tummers B., Meyers C., Biryukov J.L., Alam S., Backendorf C., et al. Human papillomavirus (HPV) upregulates the cellular deubiquitinase UCHL1 to suppress the keratinocyte's innate immune response. PLoS Pathog. 2013, 9:e1003384. 10.1371/journal.ppat.1003384.
71. Ronco L.V., Karpova A.Y., Vidal M., Howley P.M. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev. 1998, 12:2061-2072.
72. Shah M., Anwar M.A., Park S., Jafri S.S., Choi S. In silico mechanistic analysis of IRF3 inactivation and high-risk HPV E6 species-dependent drug response. Sci. Rep. 2015, 5:13446. 10.1038/srep13446.
73. Rincon-Orozco B., Halec G., Rosenberger S., Muschik D., Nindl I., Bachmann A., et al. Epigenetic silencing of interferon-kappa in human papillomavirus type 16-positive cells. Cancer Res. 2009, 69:8718-8725. 10.1158/0008-5472.CAN-09-0550.
74. Sunthamala N., Thierry F., Teissier S., Pientong C., Kongyingyoes B., Tangsiriwatthana T., et al. E2 proteins of high risk human papillomaviruses down-modulate STING and IFN-κ transcription in keratinocytes. PLoS One 2014, 9:e91473. 10.1371/journal.pone.0091473.
75. McFadden K., Luftig M.A. Interplay between DNA tumor viruses and the host DNA damage response. Curr. Top Microbiol. Immunol. 2013, 371:229-257. 10.1007/978-3-642-37765-5_9.
76. Hufbauer M., Cooke J., van der Horst G.T., Pfister H., Storey A., Akgül B. Human papillomavirus mediated inhibition of DNA damage sensing and repair drives skin carcinogenesis. Mol. Cancer 2015, 14:183. 10.1186/s12943-015-0453-7.
77. DeCarlo C.A., Severini A., Edler L., Escott N.G., Lambert P.F., Ulanova M., Zehbe I. IFN-κ, a novel type I IFN, is undetectable in HPV-positive human cervical keratinocytes. Lab. Invest. 2010, 90:1482-1491. 10.1038/labinvest.2010.95.
78. Liang D., Xiao-Feng H., Guan-Jun D., Er-Ling H., Sheng C., Ting-Ting W., et al. Activated STING enhances Tregs infiltration in the HPV-related carcinogenesis of tongue squamous cells via the c-jun/CCL22 signal. Biochim. Biophys. Acta 2015, 1852:2494-2503. 10.1016/j.bbadis.2015.08.011.
79. Mazibrada J., Longo L., Vatrano S., Cappia S., Giorcelli J., Pentenero M., et al. Differential expression of HER2, STAT3, SOX2, IFI16 and cell cycle markers during HPV-related head and neck carcinogenesis. New. Microbiol. 2014, 37:129-143.
80. Wu C., Wang Z., Song X., Feng X.S., Abnet C.C., He J., et al. Joint analysis of three genome-wide association studies of esophageal squamous cell carcinoma in Chinese populations. Nat. Genet. 2014, 46:1001-1006. 10.1038/ng.3064.